<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412371</url>
  </required_header>
  <id_info>
    <org_study_id>M14-360</org_study_id>
    <secondary_id>2016-001659-32</secondary_id>
    <nct_id>NCT02412371</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination
      with concurrent Paclitaxel/Carboplatin-based chemoradiotherapy and consolidation with
      Paclitaxel/Carboplatin-based chemotherapy (Phase 1 portion) and to assess whether the
      addition of oral veliparib versus placebo to Paclitaxel/Carboplatin-based chemoradiotherapy
      with Paclitaxel/Carboplatin consolidation will improve progression-free survival (PFS) in
      subjects with Stage III non-small cell lung cancer (Phase 2 portion).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2015</start_date>
  <completion_date type="Anticipated">March 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RPTD) of veliparib (ABT-888) in combination with radiotherapy, paclitaxel and carboplatin</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Recommended Phase 2 dose (RPTD) in combination with radiotherapy, paclitaxel and carboplatin will be determined by dose escalation in phase 1 of the study. Dose limiting toxicity (DLT) events will be collected for each dosing cohort until a new dosing cohort is opened or until the recommended Phase 2 dose is identified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the number of days from the date of enrollment to the date of earliest progression or death. If the participant does not experience disease progression or death, then the data will be censored at the date of the last disease assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response (DOR)</measure>
    <time_frame>Approximately every 8 weeks from first dose until one year after beginning therapy, then every 12 weeks for up to 3 years.</time_frame>
    <description>Duration of Overall Response (DOR) is defined as the time from the participant's initial CR or PR to the time of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately every 8 weeks from first dose until one year after beginning therapy, then every 12 weeks for up to 3 years.</time_frame>
    <description>Objective Response Rate (ORR) is defined as the proportion of the participants who have a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Overall survival is defined as the number of days from the date of participant enrollment to the date of death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Until a participant achieves 1 year on treatment (for participants in phase 2 only)</time_frame>
    <description>Two short cancer questionnaires by the European Organization for Research and Treatment of Cancer (EORTC) will be used to measure change in a participant's quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in ECOG (Eastern Cooperative Oncology Group) Performance Status of Participants</measure>
    <time_frame>Approximately 3 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Non-small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + veliparib followed by consolidation of Carbo/Pac + veliparib, is for both the Phase 1/dose escalation and Phase 2 portion of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + veliparib followed by consolidation of Carbo/Pac + Placebo, is for the Phase 2 portion of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm, concurrent radiotherapy (RT) + carboplatin (Carbo)/Paclitaxel (Pac) + placebo followed by consolidation of Carbo/Pac + placebo, is for the Phase 2 portion of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered via intravenous infusion on Day 1 of each treatment week/cycle.</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for Veliparib</intervention_name>
    <description>Oral capsule of varying doses</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered via intravenous infusion on Day 1 of each treatment week/cycle.</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Oral capsule of varying doses</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiation treatment administered on Day 1 through Day 5 of each week for approximately 30-34 visits.</description>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Veliparib</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Veliparib followed by Carbo/Pac + Placebo</arm_group_label>
    <arm_group_label>RT + Carbo/Pac + Placebo followed by Carbo/Pac + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with Histologically or cytologically confirmed Stage III non-small cell
             lung cancer (NSCLC).

          2. Participants in the randomized portion of the study must have measurable disease per
             Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.

          3. Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to
             simulation) &lt; 35%.

          4. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score
             of 0 - 1.

          5. Participant must have adequate hematologic, renal, hepatic, and lung function.

          6. Participant must consent to provide archived tissue or cytology sample of NSCLC lesion
             for analysis.

        Exclusion Criteria:

          1. Participants with prior chemotherapy or radiotherapy (RT) for current NSCLC.
             Participants curatively treated for past early stage NSCLC greater than 3 years ago
             may be included.

          2. Participants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors.

          3. Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations
             containing polyethoxylated castor oil (Cremophor).

          4. Participants with prior mediastinal or thoracic radiotherapy. Prior tangential RT to
             prior breast cancer is acceptable.

          5. Participants with major surgery in the 4 weeks prior to randomization (Video-assisted
             thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).

          6. Participants with a previous or concurrent malignancy except for treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
             patient received potentially curative treatment and has been disease-free for 3 years
             or is considered cured by the investigator if has been disease-free for less than 3
             years.

          7. Participant is pregnant or lactating.

          8. Participant with sensory peripheral neuropathy of ≥ Grade 2 at baseline, unable to
             swallow medication, or participants with prior history of seizure within the prior 12
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Service</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Maryland School Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Univ HS</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologikcy ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec a.s.</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Novy Jicin</name>
      <address>
        <city>Nový Jicín</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Prague 8 - Liben</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genl Hosp Athens Gennimatas</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Papageorgiou Hospital</name>
      <address>
        <city>NEA Efkarpia</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Gen Hosp of Patra</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bioclinic Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54622</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Euromedica General Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Fundacion Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Sta Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Genl Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Clin Univ de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Greece</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>veliparib</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>ABT-888</keyword>
  <keyword>first line</keyword>
  <keyword>previously untreated</keyword>
  <keyword>stage III</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Veliparib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

